Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This study tests eganelisib — a drug that targets an enzyme called PI3K-gamma that helps cancer cells evade the immune system — either alone or combined with cytarabine (a standard chemotherapy drug) for adults with relapsed/refractory AML (acute myeloid leukemia) or high-risk MDS (myelodysplastic syndromes, a condition where bone marrow produces abnormal blood cells). Both conditions involve the bone marrow not making healthy blood cells properly, and this study tests a new approach for patients who have run out of standard options. **You may be eligible if...** - You have relapsed or refractory AML or high-risk MDS with 10% or more abnormal cells (blasts) in your bone marrow - You are in reasonably good health (ECOG score 0-2) - Your liver and kidney function are adequate **You may NOT be eligible if...** - You had a stem cell transplant within the past 6 months - You are on immunosuppressants or systemic steroids (except for adrenal replacement) - You have an active fungal infection or any uncontrolled infection, or were not fever-free and stable for at least 72 hours on antibiotics - Your white blood cell count is very high (>25 × 10⁹/L) before treatment - You have unresolved significant side effects from prior therapy Talk to your doctor to see if this trial is right for you.